

# Xpert MTB/RIF® como herramienta diagnóstica en una cohorte de niños menores de 15 años con sospecha clínica de tuberculosis pulmonar en un hospital de alta complejidad de Medellín

Santiago León Atehortúa Muñoz<sup>a\*</sup>, Jonathan Rendón Muñoz<sup>b</sup>, Sandra Viviana Cárdenas Moreno<sup>b</sup>, Catalina Arango Ferreira<sup>a,c</sup>, José William Cornejo Ochoa<sup>c</sup>

## Resumen

**Introducción:** La tuberculosis (TB) en niños posee limitaciones en la confirmación microbiológica. Por su naturaleza paucibacilar y la dificultad para obtener muestras microbiológicas adecuadas, la positividad de cultivos es baja.

En adultos, la prueba Gene Xpert MTB/RIF® ha mostrado utilidad por su buen rendimiento, rapidez de resultados y facilidad en su realización. La Organización Mundial de la Salud (OMS) recomienda el empleo de esta prueba en niños, sin embargo, los datos de esta prueba en nuestro medio son limitados.

**Objetivo:** Estudio de cohorte retrospectivo para describir nuestra experiencia con la prueba Gene Xpert MTB/RIF en menores de 15 años hospitalizados en un centro de alta complejidad con sospecha de TB pulmonar.

**Método:** Se revisaron 116 historias clínicas con resultados disponibles de Xpert MTB/RIF en muestras respiratorias tomadas entre junio de 2012 y diciembre de 2013. Se excluyeron 33 casos. Los 83 pacientes incluidos se clasificaron como: TB confirmada 8 (10%), probable 16 (19%) y descartada 59 (71%) según criterios de la OMS. El análisis estadístico se realizó en SPSS 20 y EpiDat 3.1.

**Resultados:** Xpert MTB/RIF mostró para TB confirmada una sensibilidad del 50%, especificidad 96% y valores predictivos positivos y negativos del 57,14 y 94,7%, respectivamente. Al evaluarla en el total de niños que ameritaron inicio de tratamiento (TB confirmada y probable), la sensibilidad fue del 29% con especificidad del 100%. Xpert MTB/RIF detectó una cepa resistente a rifampicina.

**Conclusión:** Xpert MTB/RIF mostró ser útil para el diagnóstico de TB, con una sensibilidad superior a la baciloscopia. Un resultado positivo puede definir el inicio temprano de tratamiento en casos dudosos, confirma el diagnóstico y permite conocer rápidamente si existe resistencia a rifampicina. Un resultado negativo no descarta el diagnóstico ni debe impedir el inicio del tratamiento si cumple con la sumatoria de los otros criterios recomendados por la OMS.

**Palabras clave:** *Mycobacterium tuberculosis*; Tuberculosis pulmonar; Niños; Técnicas de diagnóstico molecular; Gene Xpert MTB/RIF

## Xpert MTB/RIF® as a diagnostic tool in a cohort of children under 15 years of age with clinical suspicion of pulmonary tuberculosis in a hospital of high complexity in Medellin

### Abstract

**Introduction:** Microbiological confirmation of tuberculosis (TB) in children is difficult. Due to its paucibacillary course, the positivity of cultures is low and samples are not easy to obtain.

In adults, Genexpert MTB/RIF is useful for diagnosing TB. It shows good test performance, offers fast results and is a simple technique for laboratory personnel. The World Health Organization (WHO) recommends its use for children, but clinical studies on this age group are scarce.

**Objective:** This was a retrospective, descriptive cohort study. The purpose of this study was to describe our experience with Gene Xpert MTB/RIF in children younger than 15 years of age with clinical suspicion of pulmonary TB, who were admitted to a high complexity hospital.

**Methods:** A total of 116 clinical charts with available results of Xpert MTB/RIF in respiratory samples taken between June 2012 and December 2013 were reviewed and of these, 33 were excluded. The 83 included patients were classified according to the WHO criteria into confirmed TB (n = 8; 10%), probable (n = 16; 19%) and no TB (n = 59; 71%). An analysis was performed using SPSS 20 and EpiDat 3.1.

**Results:** The Xpert MTB/RIF was 50% sensitive and 96% specific, with a positive predictive value of 57.14% and an negative predictive value of 94.7% for children with confirmed TB. When evaluating Xpert MTB/RIF in all children who received TB treatment (confirmed plus probable TB disease) the sensitivity was 29% with 100% specificity. Among our cohort, the Xpert MTB/RIF detected one child with rifampicin resistance.

**Conclusions:** Xpert MTB/RIF was useful for the diagnosis of TB. A positive result can lead to the early initiation of treatment in doubtful cases. It confirms the diagnosis and quickly reveals rifampicin resistance. A negative result, however, just as with cultures, does not exclude the diagnosis and should not prevent the initiation of treatment, if it is considered needed based on other criteria.

**Keywords:** *Mycobacterium tuberculosis*; Pulmonary tuberculosis; Child; Molecular diagnostic techniques; Gene Xpert MTB/RIF

a Servicio de Microbiología clínica, Hospital Universitario San Vicente Fundación, Medellín, Antioquia,

Recibido: 29/10/2015; Aceptado: 08/02/2015

b Universidad de Antioquia, Medellín, Antioquia,

Cómo citar este artículo: Oñate-Gutiérrez JM, et al. Prevalencia y factores relacionados con la infección por *Clostridium difficile* en un centro hospitalario de alta complejidad en Cali (Colombia). Infectio. 2016.

c Departamento de Pediatría, Universidad de Antioquia, Medellín, Antioquia,

\* Autor para correspondencia.

Correos electrónicos: satehortuam@gmail.com satehortuam@hotmail.com

(S.L. Atehortúa Muñoz).

## Conflicto de intereses

Los autores manifiestan no tener conflictos de intereses.

## Agradecimientos

Agradecemos al personal de la Unidad de Biología Molecular del Laboratorio del Hospital Universitario San Vicente Fundación y al del Laboratorio Departamental de Salud Pública por la realización de las pruebas de sensibilidad de las cepas remitidas y la ayuda con el manejo de la información.

Igualmente, agradecemos a los estudiantes de medicina de la Universidad de Antioquia, Ana María Flórez Ríos, Carlos Andrés Vargas Morales y Daniel Jaramillo Callo por la ayuda en la búsqueda y recolección de variables.

## Bibliografía

1. Organización Mundial de la Salud. Informe mundial sobre la tuberculosis 2013 [consultado 11 Mar 2015]. Disponible en:[http://apps.who.int/iris/bitstream/10665/103227/1/WHO\\_HTM\\_TB\\_2013.15\\_spain.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/103227/1/WHO_HTM_TB_2013.15_spain.pdf?ua=1). Published 2013.
2. World Health Organization. Global tuberculosis report 2015. Igarss 2014. 2015;(1):1-5.
3. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: Anti-tuberculosis treatment in children. Int J Tuber Lung Dis. 2006;10(11):1205-11 [consultado 11 Mar 2015].
4. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd edition. 2014. doi:10.1007/s007690000247.
5. Instituto Nacional de Salud. Sivigila. Boletín Epidemiológico Semanal. Semana epidemiológica número 53 de 2014 (28 dic.al 03 ene 2015). Disponible en: <http://www.ins.gov.co/boletin-epidemiologico/Boletin%20Epidemiologico/Forms/public.aspx>
6. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med. 2012;367(4):348-61.
7. Chiang SS, Swanson DS, Starke JR. New diagnostics for childhood tuberculosis. Infect Dis Clin North Am. 2015;29(3):477-502.
8. Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: A prospective study. Lancet. 2005;365(9454):130-4.
9. Starke JR. Pediatric tuberculosis: Time for a new approach. Tuberculosis. 2003;83(1-3):208-12.
10. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet Infect Dis. 2008;8(8):498-510.
11. Moreno-Pérez D, Andrés Martín A, Altet Gómez N, Baquero-Artigao F, Escribano Montaner A, Gómez-Pastrana D, et al.[Diagnosis of tuberculosis in paediatrics] [artículo en español]. An Pediatr (Barc). 2010;72(4):283.e1-14.
12. Amin I, Idrees M, Awan Z, Shahid M, Afzal S, Hussain A. PCR could be a method of choice for identification of both pulmonary and extrapulmonary tuberculosis. BMC Res Notes. 2011;4(1):332,http://dx.doi.org/10.1186/1756-0500-4-332
13. Soini H, Musser JM. Molecular diagnosis of mycobacteria. Clin Chem. 2001;47(5):809-14 [consultado 11 Mar 2015].
14. Ioannidis P, Papaventis D, Karabela S, Nikolaou S, Panagi M, Raftopoulou E, et al. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. J Clin Microbiol. 2011;49(8):3068-70.
15. Boehme CC, Nabeta P, Hillemann D, Nicol M, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005-15.
16. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB /RIF System. WHO- World Hear Organ. 2011.
17. World Health Organization. Xpert MTB/RIF implementation manual technical and operational <how-to>: practical considerations. 2014.
18. Instituto Nacional de Salud INS. Protocolo de vigilancia en salud pública: Tuberculosis. 2014:1-36. Disponible en: <http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/sivigila/Paginas/protocolos.aspx>
19. Ministerio de Salud y Protección Social. Guía Colombiana de Tuberculosis. 2015:1-30.
20. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB /RIF System. WHO- World Hear Organ. 2011.
21. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB /RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Database Syst Rev.2013;(1).
22. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid Diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: A cost-effectiveness analysis. PLoS Med. 2011;8(11):e1001120.
23. Carriquiry G, Otero L, González-Lagos E, Zamudio C, Sánchez E, Nabeta P, et al. A diagnostic accuracy study of Xpert®MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru. PLoS One. 2012;7(9):e44626.
24. Nicol MP, Workman L, Isaacs W, Munro J, Black F, Eley B, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pul-monary tuberculosis in children admitted to hospital in Cape Town, South Africa: A descriptive study. Lancet Infect Dis.2011;11(11):819-24.
25. Sekadde MP, Wobudeya E, Joloba ML, Ssengooba W, Kisembo H, Bakeera-Kitaka S, et al. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: A cross-sectional diagnostic study. BMC Infect Dis. 2013;13(1):133.
26. Nhu NT, Ha DT, Anh ND, Thu DD, Duong TN, Quang ND, et al. Evaluation of Xpert MTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis. BMC Infect Dis. 2013;13(1):31.
27. Bates M, O'Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: A prospective descriptive study. Lancet Infect Dis. 2013;13(1):36-42.
28. Oberhelman RA, Soto-Castellares G, Gilman RH, Caviedes L, Castillo ME, Kolevici L, et al. Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: A prospective case-control study. Lancet Infect Dis. 2010;10(9):612-20.
29. Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: Old wisdom and new challenges . Am J Respir Crit Care Med. 2006;173(10):1078-90.
30. Walters E, Goussard P, Bosch C, Hesseling AC, Gie RP. GeneX-pert MTB/RIF on bronchoalveolar lavage samples in children with suspected complicated intrathoracic tuberculosis: A pilotstudy. Pediatr Pulmonol. 2013;1:5.
31. Moore DP, Klugman KPMS. Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: A pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J. 2010;29:1099-104.
32. Engelbrecht AL, Marais BJ, Donald PRSH. A critical look at the diagnostic value of culture-confirmation in childhood tuberculosis. J Infect. 2006;53:364-9.
33. Castillo A. Valor diagnóstico de los criterios de Stegen modificado por Toledo en la TB infantil en el Hospital Nacional Guillermo Almenara Irigoyen. Rev Peru Pediatría. 2005;(6).
34. Marais BJ, Gie RP, Obihara CC, Hesseling AC, Schaaf HS, Beyers N. Well defined symptoms are of value in the diagnosis of childhood pulmonary tuberculosis. Arch Dis Child.2005;90(11):1162-5.
35. Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Lombard C, Enarson DA, et al. A refined symptom-based approach to diagnose pulmonary tuberculosis in children. Pediatrics.2006;118(5):e1350-9.
36. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, et al. The natural history of childhood intrathoracic tuberculosis: A critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392-402.
37. Cuevas LE, Petrucci R, Swaminathan S. Tuberculosis diagnostics for children in high-burden countries: What is available and what is needed. Paediatr Int Child Health. 2012;32 Suppl2:S30-7.